Clinical trial · Observational
N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation
Multicentric Retrospective Observation Study: Neoadjuvant Treatment and Surgery Versus Definitive Chemoradiation in the Non-Small Cell Lung Cancer (NSCLC) IIIA-N2
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this multicenter retrospective study is to compare overall survival in patients with stage IIIA-N2 NSCLC treated with neoadjuvant treatment and surgery versus definitive chemoradiation. Secondary objectives are to analyze disease-free survival, median survival, locoregional and distant relapses as well as mortality and toxicity related to treatment.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemoradiation | — | UNRESOLVED | — |
| Non-small-Cell Lung Carcinoma | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Stage IIIA-N2 | — | UNRESOLVED | — |
| Surgery | — | UNRESOLVED | — |
| Survival | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Overall survival | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Chemoradiation Group
- description
- Analyze overall survival in the group of patients treatment by Concurrent Radiotherapy (\>/= 60 Gy) plus Platinum-based Chemotherapy
- interventionNames
- Other: Overall survival
- label
- Neoadjuvant treatment plus Surgery Group
- description
- Analyze overall survival in the group of patients treatment by Neoadjuvant Platinum-based Chemotherapy or Chemoradiation (Platinum-based plus \>/= 45Gy) followed by Surgery
- interventionNames
- Other: Overall survival
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 5 years
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Stage IIIA (N2) disease * Potentially resectable disease * Stage Lung Cancer with CT scan or PET-CT. * N2 involvement: it is not necessary pathological proof. * No progression after induction treatment. Exclusion Criteria: * T4 or N3 stage. * Bulky disease or not resectable.
References
Publications (0)
Data not yet available